# Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors

> **NCT03324113** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 34 (actual)

## Conditions studied

- Neoplasm Malignant

## Interventions

- **DRUG:** SAR408701
- **DRUG:** dexamethasone
- **DRUG:** naphazoline
- **DRUG:** diphenhydramine

## Key facts

- **NCT ID:** NCT03324113
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-17
- **Primary completion:** 2022-11-18
- **Final completion:** 2022-12-26
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03324113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03324113, "Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03324113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*